Edition:
India

People: Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

144.55EUR
6:07pm IST
Change (% chg)

€1.05 (+0.73%)
Prev Close
€143.50
Open
€143.80
Day's High
€145.65
Day's Low
€143.60
Volume
80,039
Avg. Vol
374,154
52-wk High
€171.20
52-wk Low
€74.48

Cautreels, Werner 

Dr. Werner Cautreels, Ph.D. has been Non-Executive Independent Director of Galapagos NV since June 2, 2009. He is Member of the Company's Nomination and Remuneration Committee and Chairman of the Company's Audit Committee. He is President and Chief Executive Officer (CEO) of Selecta Biosciences, Inc. Previously, Dr. Cautreels was Global CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in February 2010. Prior to joining Solvay he was employed by Sanofi, Sterling Winthrop and Nycomed Amersham in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels was a Director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, United States) from 1999 to 2006. He was President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. Dr. Werner Cautreels graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He also holds a Bachelors degree and Master of Science in Chemistry from the University of Antwerp. He received his management and financial education from the Harvard Business School.

Basic Compensation

Total Annual Compensation, EUR 55,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 55,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --